Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a pilot study evaluating the feasibility of using adaptive intermittent dosing of
vemurafenib and cobimetinib in BRAF mutant patients with elevated baseline lactate
dehydrogenase (LDH).
The purpose of this study is to determine whether an intermittent adaptive dosing of
vemurafenib and cobimetinib may be superior to standard, continuous dosing with these study
drugs.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute